5-Amino-1MQ (10 mg Vial) Dosage Reference

Dosing & Reconstitution Guide

The source page reports two example amounts. The last two columns are transparent volume conversions using a 10 mg sample brought to a final volume of 2.0 mL.

Reference phase	Reported amount	At 5 mg/mL	U-100 scale equivalent
Lower reported reference	2.5 mg	0.50 mL	50 units
Higher reported reference	5 mg	1.00 mL	100 units

These figures summarize an external educational page and are not a Newt dosing recommendation. “Units” are included only as a U-100 volume-scale conversion.

Transparent math

Subcutaneous Protocol (2 mL = 5 mg/mL)

The cited page describes a 10 mg format brought to a final volume of 2.0 mL. Newt preserves its concentration math for source review, not as an administration recommendation.

10 mg ÷ 2.0 mL = 5 mg/mL. The source reports 2.5 mg and 5 mg amounts, which correspond mathematically to 0.50 mL and 1.00 mL at that concentration.

Days 1–2 source value
The external page labels 2.5 mg as its tolerance-phase amount.
Day 3+ source value
The external page labels 5 mg as its standard amount.
Alternative source schedule
The source also describes dividing its reported amount; this is a source claim, not Newt guidance.

Reconstitution Steps

Use a sterile syringe to draw the validated diluent volume specified by the selected vial-format table, product label or approved laboratory method.
Inject the diluent slowly down the inside wall of the vial; avoid directing the stream onto the material and avoid foaming.
Gently swirl or roll until fully dissolved. Do not shake.
Label the vial with product, concentration, diluent, preparation date and operator; protect from light and refrigerate at 2–8 °C (35.6–46.4 °F) unless the product-specific method states otherwise.
Use within the product-specific validated hold time and no later than 4 weeks after preparation unless published stability data supports a different period.

Supplies Needed

Product vial (5-Amino-1MQ; use the selected labelled vial strength).
U-100 insulin syringe (1 mL capacity) or the sterile administration device specified by the approved protocol.
Validated diluent in the container size specified by the product label or authorized preparation method.
Alcohol swabs and an approved sharps container—use a fresh swab for the vial stopper and each administration site.

Source interpretation

Protocol Overview

The cited page presents a human-oriented protocol. Newt records its key data points without presenting them as administration guidance.

The source uses a 10 mg format, 2.0 mL final volume and a calculated concentration of 5 mg/mL. It associates 2.5 mg and 5 mg references with a daily schedule.

These remain third-party educational claims and do not establish safety, efficacy, route or schedule for any person.

External values

Dosing Protocol

The source’s reported sequence is summarized for fidelity without converting it into Newt medical guidance.

Starting source amount
The source describes 2.5 mg once daily as an initial tolerance reference.
Target source amount
The source describes 5 mg once daily or a divided 2.5 mg twice-daily reference.
Format-duration statement
The source states that one 10 mg vial represents two to four days at its described values.
Evidence boundary
These values are not clinically established recommendations and are not endorsed by Newt.

Storage Instructions

Proper storage helps maintain product quality and stability. The supplied label, COA and product-specific validated method take precedence over these general handling rules.

Unopened: Keep the vial sealed, dry and protected from light at the temperature stated on the supplied label; do not assume a universal shelf life.
After preparation: Refrigerate at 2–8 °C (35.6–46.4 °F) unless the product-specific method states otherwise, and use only within its validated in-use period.
Before opening a cold vial, allow the sealed container to equilibrate as required by the method so condensation does not enter the product.
Long-term storage: Freeze or aliquot only when supported by product-specific stability data; avoid repeated freeze–thaw cycles and discard material with unexpected particles, discoloration or container damage.

Read before use

Important Notes

Not a peptide
5-Amino-1MQ is a small molecule rather than a peptide sequence.
No clinical recommendation
This guide does not select a dose, route, schedule or treatment plan.
Recalculate every format
Do not reuse the 10 mg / 2.0 mL calculations for another mass, volume or product.
Qualified oversight required
Research planning should follow applicable rules, institutional review and qualified oversight.

How This Works

5-Amino-1MQ is a small-molecule inhibitor used in preclinical NNMT research.

NNMT transfers a methyl group from S-adenosylmethionine to nicotinamide, connecting nicotinamide metabolism, methyl-donor balance and 1-methylnicotinamide production.

Cell and animal studies examine how NNMT inhibition changes these metabolites and downstream energy-regulation pathways. This does not establish a clinical use.

Benefits & Side Effects

Benefits

Preclinical metabolic findings: Mouse and cell studies report changes in adiposity, metabolites and energy-related pathways under specific conditions.
Study context matters: Species, diet, formulation, analytical method, exposure and duration can materially change results.

Side Effects & Evidence Limits

No established human benefit: Preclinical outcomes cannot establish a proven benefit or safe amount for people.
Safety is not defined: The source lists possible reactions, but high-quality clinical safety data and an approved indication are not established.

Source context

Lifestyle Factors

The external page pairs its discussion with general diet, exercise, sleep and stress-management suggestions.

These are general wellness statements, not evidence that a lifestyle intervention changes the safety or effectiveness of 5-Amino-1MQ.

Newt does not reproduce the source’s supplement-stacking suggestion because interaction and clinical-safety evidence is not established.

Injection Technique

Use this technique only when the product-specific approved label or authorized research protocol specifies subcutaneous administration and trained personnel are responsible for the procedure.

Clean the vial stopper and the selected administration site with alcohol; allow both surfaces to dry completely.
Pinch a small fold of skin and insert the needle into the subcutaneous tissue at a 45–90° angle.
Do not aspirate during a subcutaneous injection; deliver the validated volume slowly and steadily.
If the approved protocol specifies a volume greater than 1.0 mL, divide it between separate sites rather than using one site.
Rotate sites systematically; commonly referenced subcutaneous sites include the abdomen, thigh and upper arm.
Wait several seconds after delivery before withdrawing the needle to help ensure the complete validated volume is delivered.
Discard the used syringe immediately in an approved sharps container; never recap or reuse it.